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circulating extracellular VEGF (4). The investigators (1) stated
that “serum was separated after coagulation,” but they did not
report the interval between venipuncture and separation of serum
from blood cell; this interval should be standardized and declared.
In serum, VEGF concentrations increase in a time-dependent
manner (5). In a clinical situation, where blood samples are taken
and left for variable times before processing, the contribution from
the clotting process would make the measurement unreliable (5).
Allowing the whole blood sample to clot for between 2 and 6 h
before serum is collected reduces time-dependent, nonuniform
release of VEGF (6). In addition, the researchers did not report the
conditions of processing (centrifugal force and the length of
centrifugation), which are relevant and should be standardized.
Finally, a direct correlation between platelet counts and serum
VEGF has been described (6). When serum is used for the
measurement of VEGF, it is advisable to correct the results for
variations in platelet count and platelet size (3).
In conclusion, meticulous standardization of sampling is a
mandatory step in studies on blood VEGF levels. The investiga-
tors’ conclusion that “serum VEGF levels were not significantly
elevated in obese versus lean subjects” cannot be justified on the
basis of the data presented.
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REPLY
We would like to thank Dr. Ferrero for the comments regarding
our study, which demonstrated that obesity was associated with an
increase in serum hepatocyte growth factor (HGF) levels (1). Our
study also showed a nonsignificant trend toward higher vascular
endothelial growth factor (VEGF) levels in the serum of obese
subjects. As Dr. Ferrero correctly points out, the time between
collection of blood samples and the time when the serum is
centrifuged can affect the concentrations of growth factors like
VEGF. We are not aware of any clear directional bias in our study
related to serum collection that would have resulted in low levels of
serum VEGF in obese subjects and thus masked higher circulating
VEGF levels. However, VEGF levels did demonstrate marked
interindividual variability, and this may have contributed to the
absence of a statistically significant difference of VEGF levels
between obese and nonobese subjects. It is quite possible that
serum HGF levels may be more robustly associated with obesity,
whereas serum VEGF levels may be a reflection of not just obesity
but also other co-morbidities and factors like the serum clotting
time.
Furthermore, a more recent study was indeed able to show that
serum VEGF levels are associated with obesity (2). Interestingly,
the researchers in that study found that visceral fat area showed a
better correlation with circulating VEGF levels than did body mass
index. This may reflect a greater contribution of visceral fat to
circulating VEGF levels than other fat tissues.
Finally, we believe that the association between obesity and
vascular growth factor is an exciting and rapidly growing area of
research, and it will continue to enhance our knowledge of how
obesity can affect both the vasculature and atherosclerosis.
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